VERU · Veru Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $16.89M | $16.3M | $39.35M | $61.26M | $42.59M | $31.8M | $15.86M | $13.66M | $22.13M | $32.6M | $24.49M | $31.46M | $35.03M | $18.57K | $22.22M | $27.54M | |
| — | — | $11.03M | $8.73M | $8.76M | $13.33M | $11.81M | $10.15M | $7.09M | $6.64M | $8.78M | $13.63M | $11.37M | $13.95M | $14.41M | $8.7M | $9.3M | $14.03M | |
| — | — | $5.85M | $7.57M | $30.59M | $47.93M | $30.79M | $21.66M | $8.77M | $7.02M | $13.35M | $18.97M | $13.12M | $17.5M | $20.62M | $9.87M | $12.92M | $13.52M | |
| — | — | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.1% | 55.3% | 51.4% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53138.65% | 58.16% | 49.08% | |
| $11.76M | $15.59M | $12.78M | $51.2M | $70.91M | $32.69M | $16.94M | $13.74M | $10.85M | $3.08M | $99.39K | $219.82K | $5575 | $4745 | $5277 | $10.93K | $381 | $105.92K | |
| $16.05M | $19.94M | $24.61M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $31.18M | $48.06M | $43.18M | $20.67M | $14.5M | $14.35M | $14.81M | $11.5M | $8.66M | $12.13M | $9.13M | $7.49M | $9.63M | $6.54M | $6.57M | $7.01M | |
| — | — | — | $71K | $71K | $113K | $316K | $309.23K | $275.26K | $147.01K | — | — | — | — | — | — | — | — | |
| $113.15K | $152.11K | $268.18K | $269.87K | — | — | — | — | $176.79K | $334K | $422.87K | $494.26K | $589.34K | $556.3K | $461.45K | $464.91K | $466.54K | $268.38K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.93M | — | |
| $27.82M | $35.53M | $37.39M | $107.07M | $114.08M | $53.36M | $31.43M | $28.09M | $29.64M | $15.51M | $10.33M | $12.35M | $9.2M | $7.71M | $9.68M | $6.57M | $8.58M | $8.8M | |
| -$19.19M | -$24.75M | -$36.17M | -$93.78M | -$83.49M | $12.97M | -$14.75M | -$6.44M | -$20.87M | -$8.49M | $3.02M | $6.62M | $3.92M | $9.79M | $10.94M | $3.3M | $4.35M | $4.72M | |
| — | — | -214.19% | -575.46% | -212.14% | 21.18% | -34.62% | -20.24% | -131.57% | -62.2% | 13.64% | 20.3% | 16.02% | 31.12% | 31.23% | 17750.29% | 19.57% | 17.13% | |
| -$19.08M | -$24.6M | -$35.9M | -$93.51M | — | — | — | — | -$20.7M | -$8.16M | $3.44M | $7.11M | $4.51M | $10.35M | $11.4M | $3.76M | $4.82M | $4.99M | |
| — | — | $607.47K | $2.43M | $4.37M | $4.89M | $4.62M | $4.71M | $2.95M | — | — | — | — | — | — | — | — | — | |
| $5.08M | $9.07M | $909.12K | $1.11M | -$316.06K | -$8.71M | -$5.31M | -$5.89M | -$2.2M | -$108.38K | -$204.6K | $68.63K | $33.28K | $144.26K | -$147.91K | -$63.37K | — | — | |
| — | — | — | -$92.67M | -$83.8M | $4.27M | -$20.05M | -$12.32M | -$23.07M | -$8.6M | $2.81M | $6.69M | $3.96M | $9.93M | $10.79M | $3.23M | $4.22M | — | |
| $0 | $0 | $0 | $480.21K | $236.4K | -$3.13M | -$1.08M | -$303.93K | $866.1K | -$1.99M | $2.47M | $2.34M | $1.52M | -$4.41M | -$4.51M | -$2.17M | -$2.51M | -$1.49M | |
| -$13.61M | -$22.73M | -$37.8M | -$93.15M | -$84.04M | $7.39M | -$18.97M | -$12.02M | -$23.94M | -$6.61M | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.54M | |
| — | — | -223.86% | -571.6% | -213.55% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29081.88% | 30.32% | 23.73% | |
| — | — | — | — | — | — | — | — | -$23.94M | -$8.6M | $344.73K | $4.35M | — | — | — | $5.4M | $6.74M | $6.46M | |
| — | — | — | — | — | — | — | — | — | — | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.12M | |
| USD/shares | -$0.58 | -$1.55 | -$2.80 | -$11.00 | -$10.50 | $1.00 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.90 | $5.10 | $5.50 | $2.00 | $2.50 | $2.50 |
| USD/shares | — | — | — | -$11.00 | -$10.50 | $0.90 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.80 | $5.00 | $5.30 | $1.90 | $2.40 | $2.40 |
| shares | — | 14.65M | 13.49M | 8.5M | 8.01M | 7.63M | 6.68M | 6.33M | 5.39M | 3.46M | 2.87M | 2.85M | 2.85M | 2.84M | 2.77M | 2.73M | 2.7M | 2.57M |
| shares | — | — | — | 8.5M | 8.01M | 8.38M | 6.68M | 6.33M | 5.39M | 3.46M | 2.89M | 2.89M | 2.89M | 2.87M | 2.89M | 2.9M | 2.85M | 2.78M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2015: $5.64M in buybacks, $31.51M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 775,157 | 10-Q filed 2026-08-10 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 1,907,735 | 10-Q filed 2026-08-10 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 300 similar-size Biotechnology companies (of 588 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| FC2 Segment | $60,396,697 | $40,556,818 |
| Preboost Segment | $862,831 | $2,035,242 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| United States | $5,354,090 | $8,370,202 | $31,430,235 | $48,938,821 | $30,338,115 |
| Other Geographical Areas | $4,696,800 | $5,985,078 | — | — | — |
| Brazil | $2,760,540 | — | — | — | — |
| Mozambique | $2,172,840 | — | — | — | — |
| South Africa | $1,902,149 | $1,941,678 | — | — | — |
| Other Countries | — | — | $7,924,117 | $12,320,707 | $12,253,945 |
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| FC2 Female Condom | $16,886,419 | $16,283,945 | — | — |
| Product And Service Other | $0 | $13,013 | — | — |
| FC2 Global Public Health Sector | — | — | $9,128,858 | $13,926,249 |
| FC2 U.S. Prescription Channel | — | — | $30,223,079 | $46,470,448 |
| Other Products | — | — | $2,415 | $862,831 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Sexual Health Segment | $44,015,921,000 | $26,495,126,000 |
| Corporate | $2,346,851,000 | -$24,370,763,000 |
| Research and Development Segment | -$33,390,115,000 | -$16,871,057,000 |